REG - Indivior PLC - Indivior to Participate in Conference

IndiviorAnnouncement

25/04/2023 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230425:nRSY3855Xa&default-theme=true

RNS Number : 3855X  Indivior PLC  25 April 2023

 

 

Indivior To Participate In Bank of America Global Healthcare Conference 2023

 

Slough, UK, and Richmond, VA, April 25, 2023 - Indivior PLC (LSE: INDV) today
announced that it will participate in the following investor event:

 

·    Bank of America Global Healthcare Conference 2023 - Las Vegas

Mark Crossley, CEO, will host 1x1/group meetings on Wednesday and Thursday,
May 10(th) and 11(th) and host a presentation Wednesday May 10(th) at 5:00
p.m. US PDT (8:00 p.m. US EST).  Investors can contact their Bank of America
representative to schedule a meeting.  The presentation will be available at
www.indivior.com (http://www.indivior.com) and can also be viewed using the
following webcast link:
https://bofa.veracast.com/webcasts/bofa/healthcare2023/idvYkp0I.cfm
(https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fbofa.veracast.com%2Fwebcasts%2Fbofa%2Fhealthcare2023%2FidvYkp0I.cfm&data=05%7C01%7Ctimothy.owens%40Indivior.com%7Ca4f9ec6c00f544714eb908db44bfcefb%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638179362905397610%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=RgPps2OpaH6p0CNN2cspZHe%2BdoLHW7J%2BkRDrIeSHPfo%3D&reserved=0)

 

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to

treat substance use disorders (SUD) and serious mental illnesses. Our vision
is that all patients around the world

will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in 39
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANLSAESDEEA